Filing Flows › Comparisons › NEO vs AIDX
Neogenomics vs 20/20 Biolabs: NEO and AIDX compared
Neogenomics is the larger company: $209M of revenue in its latest quarter (Q3 2026) against $731K for 20/20 Biolabs (Q2 2026). 20/20 Biolabs is growing faster (+36% against +11% a year earlier). Neogenomics is more profitable, with an operating margin of -3.8% against -170.3%.
Where the money goes: NEO and AIDX
Neogenomics (NEO) · Q3 2026
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
20/20 Biolabs (AIDX) · Q2 2026
20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%, net loss $1.5M, operating cash flow −$605K. The chart follows the revenue to costs, profit and cash.
| Neogenomics (NEO) | 20/20 Biolabs (AIDX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $209M | $731K |
| Revenue growth, Y/Y | +11% | +36% |
| Operating margin | -3.8% | -170.3% |
| Net earnings | −$7.5M | −$1.5M |
| Net margin | -3.6% | -206.2% |
| Operating cash flow | −$8.9M | −$605K |
Where the revenue comes from
Neogenomics
- Client direct billing: $136M (65%)
- Commercial insurance: $44.7M (21%)
- Medicare and other government: $29.0M (14%)
20/20 Biolabs
- OneTest: $696K (95%)
- BioCheck: $35K (5%)
Questions
Which is bigger, Neogenomics or 20/20 Biolabs?
Neogenomics is the larger company: $209M of revenue in its latest quarter (Q3 2026) against $731K for 20/20 Biolabs (Q2 2026).
Is Neogenomics or 20/20 Biolabs growing faster?
20/20 Biolabs is growing faster (+36% against +11% a year earlier).
Which is more profitable, Neogenomics or 20/20 Biolabs?
Neogenomics is more profitable, with an operating margin of -3.8% against -170.3%.
More: Neogenomics earnings · how Neogenomics makes money · 20/20 Biolabs earnings · how 20/20 Biolabs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 28, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.